Clinical trial
National Study Backed by a Rare Disease Cohort the Benefit / Risk Balance of Immunomodulatory Treatments Prescribed in the Child and Adolescent for Autoimmune Cytopenia.
NCT04057703 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- National Study Backed by a Rare Disease Cohort the Benefit / Risk Balance of Immunomodulatory Treatments Prescribed in the Child and Adolescent for Autoimmune Cytopenia.
- Lead sponsor
- University Hospital, Bordeaux
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 18, 2016
- Completion date
- December 4, 2016
- Enrollment
- 454 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune hemolytic anemia, evan syndrome, immune thrombocytopenic purpura, immunotherapy